BMP4处理的原代胶质瘤培养物的单细胞RNA测序比较分析揭示治疗标志物
该研究对17例BMP4处理的患者来源胶质母细胞瘤培养物评估细胞活力,并对高敏感和低敏感各一例进行单细胞RNA测序。结果显示BMP4敏感性差异大,OLIG1/2水平可预测高敏感性,RPL27A和RPS27在敏感培养物中一天内上调,为早期反应标志物。
要点
- BMP4处理的患者来源胶质母细胞瘤培养物细胞活力差异大。
- OLIG1/2表达可预测对BMP4的高敏感性。
- RPL27A和RPS27上调是BMP4敏感性的早期反应标志物。
核心结论
- BMP4处理患者来源胶质母细胞瘤培养物后的细胞组成变化与治疗效果相关。
- OLIG1/2表达可预测该疗效,RPL27A和RPS27上调是有用的早期反应标志物。
研究设计与样本
- 对17例BMP4处理的患者来源胶质母细胞瘤培养物评估细胞活力。
- 选择一例高敏感(高疗效)和一例低敏感培养物进行单细胞RNA测序,分析细胞簇相对丰度,寻找并鉴定预测性和早期反应标志物,并在全部17例培养物中验证。
主要发现
- BMP4处理后细胞活力变异大。
- 在三例对BMP4敏感性最高的培养物中,形成了大量新的细胞亚群,这些细胞增殖减少、凋亡增加。
- 在BMP4敏感性低的培养物中,神经元分化减少最明显。
- OLIG1/2水平可预测对BMP4的高敏感性。
- 在非常敏感的培养物中,核糖体翻译激活标志物RPL27A和RPS27在一天内上调。
关键数值与推荐
- OLIG1/2水平可预测对BMP4的高敏感性。
- RPL27A和RPS27上调可作为BMP4敏感性的早期反应标志物。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioblastoma (GBM) is the most aggressive primary brain tumor. Its cellular composition is very heterogeneous, with cells exhibiting stem-cell characteristics (GSCs) that co-determine therapy resistance and tumor recurrence. Bone Morphogenetic Protein (BMP)-4 promotes astroglial and suppresses oligodendrocyte differentiation in GSCs, processes associated with superior patient prognosis. We characterized variability in cell viability of patient-derived GBM cultures in response to BMP4 and, based on single-cell transcriptome profiling, propose predictive positive and early-response markers for sensitivity to BMP4. METHODS: Cell viability was assessed in 17 BMP4-treated patient-derived GBM cultures. In two cultures, one highly-sensitive to BMP4 (high therapeutic efficacy) and one with low-sensitivity, response to treatment with BMP4 was characterized. We applied single-cell RNA-sequencing, analyzed the relative abundance of cell clusters, searched for and identified the aforementioned two marker types, and validated these results in all 17 cultures. RESULTS: High variation in cell viability was observed after treatment with BMP4. In three cultures with highest sensitivity for BMP4, a substantial new cell subpopulation formed. These cells displayed decreased cell proliferation and increased apoptosis. Neuronal differentiation was reduced most in cultures with little sensitivity for BMP4. OLIG1/2 levels were found predictive for high sensitivity to BMP4. Activation of ribosomal translation (RPL27A, RPS27) was up-regulated within one day in cultures that were very sensitive to BMP4. CONCLUSION: The changes in composition of patient-derived GBM cultures obtained after treatment with BMP4 correlate with treatment efficacy. OLIG1/2 expression can predict this efficacy, and upregulation of RPL27A and RPS27 are useful early-response markers.
引用
- Verploegh ISC, Conidi A, Brouwer RWW, et al. Comparative single-cell RNA-sequencing profiling of BMP4-treated primary glioma cultures reveals therapeutic markers. Neuro Oncol. 2022. PMID: 35639831. doi:10.1093/neuonc/noac143
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。